No toxic financing, and the O/S is indeed 500 mil. Most of that is due to controlled dilution by the company, as they sold on the open market to aquire funds. They were very upfront about it and a month or so ago I post an email in which they explained why they did it. But they owe no money to viper company's like Cornell and that is very good in my book.